Sensors (Jul 2022)

Ti<sub>2</sub>C-TiO<sub>2</sub> MXene Nanocomposite-Based High-Efficiency Non-Enzymatic Glucose Sensing Platform for Diabetes Monitoring

  • Vinod Kumar,
  • Sudheesh K. Shukla,
  • Meenakshi Choudhary,
  • Jalaj Gupta,
  • Priyanka Chaudhary,
  • Saurabh Srivastava,
  • Mukesh Kumar,
  • Manoj Kumar,
  • Devojit Kumar Sarma,
  • Bal Chandra Yadav,
  • Vinod Verma

DOI
https://doi.org/10.3390/s22155589
Journal volume & issue
Vol. 22, no. 15
p. 5589

Abstract

Read online

Diabetes is a major health challenge, and it is linked to a number of serious health issues, including cardiovascular disease (heart attack and stroke), diabetic nephropathy (kidney damage or failure), and birth defects. The detection of glucose has a direct and significant clinical importance in the management of diabetes. Herein, we demonstrate the application of in-situ synthesized Ti2C-TiO2 MXene nanocomposite for high throughput non-enzymatic electrochemical sensing of glucose. The nanocomposite was synthesized by controlled oxidation of Ti2C-MXene nanosheets using H2O2 at room temperature. The oxidation results in the opening up of Ti2C-MXene nanosheets and the formation of TiO2 nanocrystals on their surfaces as revealed in microscopic and spectroscopic analysis. Nanocomposite exhibited considerably high electrochemical response than parent Ti2C MXene, and hence utilized as a novel electrode material for enzyme-free sensitive and specific detection of glucose. Developed nanocomposite-based non-enzymatic glucose sensor (NEGS) displays a wide linearity range (0.1 µM-200 µM, R2 = 0.992), high sensitivity of 75.32 μA mM−1 cm−2, a low limit of detection (0.12 μM) and a rapid response time (~3s). NEGS has further shown a high level of repeatability and selectivity for glucose in serum spiked samples. The unveiled excellent sensing performance of NEGS is credited to synergistically improved electrochemical response of Ti2C MXene and TiO2 nanoparticles. All of these attributes highlight the potential of MXene nanocomposite as a next-generation NEGS for on the spot mass screening of diabetic patients.

Keywords